Advisor OS LLC Sells 628 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Advisor OS LLC reduced its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,405 shares of the company’s stock after selling 628 shares during the quarter. Advisor OS LLC owned 0.05% of Amphastar Pharmaceuticals worth $943,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of AMPH. Raymond James & Associates increased its stake in Amphastar Pharmaceuticals by 1.7% during the 3rd quarter. Raymond James & Associates now owns 116,677 shares of the company’s stock worth $5,662,000 after purchasing an additional 1,958 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth $11,070,000. Dakota Wealth Management bought a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth $202,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after acquiring an additional 301 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in Amphastar Pharmaceuticals by 63.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,362 shares of the company’s stock valued at $454,000 after acquiring an additional 3,617 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Piper Sandler cut Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $66.00 to $36.00 in a report on Tuesday, February 4th. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective for the company. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of “Hold” and an average target price of $50.33.

Amphastar Pharmaceuticals Trading Down 0.9 %

Shares of NASDAQ:AMPH opened at $31.99 on Wednesday. The company’s 50-day moving average price is $35.27 and its two-hundred day moving average price is $42.83. Amphastar Pharmaceuticals, Inc. has a one year low of $30.34 and a one year high of $56.38. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The stock has a market capitalization of $1.54 billion, a PE ratio of 10.66, a price-to-earnings-growth ratio of 2.19 and a beta of 0.81.

Insider Activity at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 7,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the transaction, the executive vice president now directly owns 118,469 shares in the company, valued at approximately $5,262,392.98. The trade was a 5.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the completion of the sale, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. This represents a 24.71 % decrease in their position. The disclosure for this sale can be found here. 27.10% of the stock is owned by company insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.